|1.||Seasonal Allergic Rhinitis (Hay Fever)
09/01/1982 - "During 4 weeks of the grass pollen season in the south of Sweden 27 patients with seasonal allergic rhinitis were treated topically with a beta-adrenoceptor stimulant, KWD 2131, which in an earlier rhinomanometric study had shown a prophylactic effect at nasal allergen provocations in hay-fever patients. "
09/01/1982 - "Topical treatment of seasonal allergic rhinitis with a beta-adrenoceptor stimulant (KWD 2131)."
01/01/1980 - "The effects of the beta-adrenoceptor stimulating drugs, terbutaline (Bricanyl) and KWD 2131, on the increase in nasal airway resistance induced by pollen extracts, have been studied in a placebo-controlled double-blind crossover trial of 13 asymptomatic (out of season) patients with hay fever. "
|3.||Asthma (Bronchial Asthma)
07/01/1980 - "The selective anti-allergic effect of a new beta-agonist, KWD 2131, in inhibiting allergen-provoked asthma was compared with that of placebo in a double-blind crossover study. "
03/01/1980 - "Pretreatment with KWD 2131, before histamine challenge, showed that the subthreshold dose for bronchodilatation was 0.5 mg in nine patients and 0.25 mg in three patients compared with 1 mg in patients with intrinsic asthma. "
03/01/1980 - "The equipotent bronchodilating doses of terbutaline and a new beta-agonist KWD 2131 with a relatively stronger anti-allergic (inhibition of mediator release) than bronchodilating effect given in nebulized form was estimated in eight patients with intrinsic asthma. "
07/01/1980 - "Evaluation of the protective effect of a new beta-agonist, KWD 2131, on allergen-induced bronchospasm."
08/01/1982 - "The anti-allergic capacity of nebulized KWD 2131 in inhibiting allergen-induced bronchospasm was compared with that of terbutaline in equipotent bronchodilating doses. "
08/01/1982 - "The protective property of equipotent bronchodilating doses of inhaled KWD 2131 and terbutaline against allergen-induced bronchospasm."
|2.||Histamine (Histamine Dihydrochloride)